The group’s principal activities include developing and commercializing novel therapeutic treatments. The products of the group include Zingo(TM) and 4975. The group products sold under the trade names Avrina(TM) and Zingo(TM). In December 2005, the group merged with AlgoRx Pharmaceuticals, Inc. Specific customers of the group include Johnson & Johnson, Purdue Pharma and Genzyme. The group operates from the United States. The revenue of the group for the year 2006 was $89,000.
